Therefore, it is still speculative whether EGF levels in MS CNS may serve as an effective tool in the MS diagnosis and/or as an useful biomarker to discriminate the clinical forms of MS, as it has been shown in plasma of MS patients (Tejera-Alhambra et al. 2015). This evidence concerns the gene EGF and myeloid sarcoma.